Drug release technology developer Rani has now raised $211m in all, from investors including GV, Novartis, Ping An Ventures, KPC, AstraZeneca and Stevanato.
Rani Therapeutics, a US-based oral drug delivery technology developer backed by multiple corporate investors, has received $69m in series E funding from unnamed investors.
Founded in 2012, Rani has devised a large-molecule pill called RaniPill that functions as an alternative to medical injections, facilitating the use of oral drugs to treat chronic diseases such as diabetes, arthritis and psoriasis.
The series E cash will help the company upgrade its manufacturing capacity and advance its clinical-stage drug development activities, which include…
